A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia.

Publication Type:

Journal Article

Source:

Clinical lymphoma, myeloma & leukemia, Volume 14, Issue 5, p.395-400.e1 (2014)

Keywords:

2014, April 2014, Center-Authored Paper, Clinical Research Division, Flow Cytometry Core Facility, Research Trials Office Core Facility - Biostatistics Service, Specimen Processing Core Facility

Abstract:

The combination of cytarabine and fludarabine was associated with superior clinical outcomes compared with those of high-dose cytarabine in relapse acute myeloid leukemia (AML). We conducted a phase I study combining oxaliplatin with cytarabine and fludarabine therapy for patients with relapsed or refractory AML.